Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
Researchers developed TAMENDOX to supplement (Z)-endoxifen in patients with CYP2D6 enzyme deficiency, improving drug concentration and effectiveness. The new therapy was well-tolerated, showing promise as an alternative to aromatase inhibitors for premenopausal women.
Researchers at UC Irvine have identified a new way to protect the brain from cognitive decline caused by cranial radiation therapy. The study found that targeting a specific immune response pathway can improve memory and cognition in mice with and without brain cancer.
Researchers at UT Austin have developed a new cancer treatment that uses LED light and SnOx nanoflakes to precisely target cancer cells without harming healthy ones. The treatment achieved remarkable effectiveness in neutralizing colorectal and skin cancer cells, with up to 92% kill rate in just 30 minutes of exposure.
Researchers found that patients with stage III or IV cancer who quit smoking lived significantly longer than those who continued smoking, with a two-fold lower rate of all-cause mortality. The study's findings emphasize the crucial role of smoking cessation support as part of standard cancer care.
Researchers found that quitting smoking more than doubles survival time among patients with advanced cancers. The study shows the benefits of integrated smoking cessation interventions into cancer treatment plans.
Researchers create novel antibody-based treatment that combines diagnostic and therapeutic capabilities to target LRRC15-expressing tumors, slowing growth and extending survival. The approach shows promise in preclinical models by priming tumors for immune response and boosting immunotherapy's effectiveness.
Researchers found that 27% of breast cancer cases have genetic features guiding personalized treatment immediately. The study identified over 8,300 cases suitable for future research, providing insights into prognosis and potential new treatments.
Research found that inflammatory markers are linked to different aspects of cancer-related fatigue, with some effects persisting after treatment. The study suggests targeting inflammation for developing treatments to alleviate this debilitating symptom.
Researchers discovered that an enzyme called EZH2 drives triple negative breast cancer cells to divide abnormally, enabling them to spread. Inhibiting EZH2 with drugs like tazemetostat restored order to dividing cells and thwarted the spread of TNBC cells.
A topical formulation has been shown to reduce the incidence of hand-foot neuropathy in cancer patients undergoing chemotherapy, improving quality of life. The cream, developed at UMH, acts directly on neurosensory pain receptors, reducing hypersensitivity and tolerance to chemotherapy.
Researchers at CNIO have created a 'human repairome', a catalogue of 20,000 DNA 'scars' that reveal how genes affect DNA repair. This information can help determine the best treatment for each cancer type and overcome resistance to therapy.
A study found that stereotactic body radiotherapy (SBRT) after prostate surgery is safe and effective in preventing cancer recurrence, with low side effects and manageable treatment. The results suggest SBRT may be a faster and simpler option for men at risk of recurrent prostate cancer.
A diet rich in cysteine has been shown to activate immune cells that help regenerate intestinal tissue, potentially offering a new way to heal tissue damage from radiation or chemotherapy treatment. The researchers found that cysteine initiates a chain of events leading to the activation of CD8 T cells, which produce cytokines like IL-...
A new herpes virus-based vaccine has been developed that targets cancer cells while sparing healthy tissue. The vaccine, which includes a gene encoding the protein decorin, was shown to enhance its cancer-killing effect on lung cancer cells and reduce tumour angiogenesis in liver cancer in chicken embryos.
Researchers at Fox Chase Cancer Center demonstrate that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce severe side effects, such as painful swallowing problems, while maintaining treatment effectiveness for patients with esophageal and non-small cell lung cancer. The study's key findings show that PLDR brea...
Researchers identified two lymphocyte subpopulations associated with arsenic trioxide therapy for APL, the CD8 ISG T cells and NK NFκB cells, which provide new insights into its mechanism of action. ATO treatment also revitalized dysfunctional NK cells and remodelled immunoglobulin proteins.
The TORPEdO trial found that intensity-modulated radiotherapy (IMRT) is as effective as proton beam therapy (PBT) in treating head and neck cancer. Both treatments delivered similar outcomes in terms of survival and quality of life, with IMRT being more widely available.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.
A new PSMA-targeting radioligand therapy added to stereotactic body radiotherapy (SBRT) more than doubled progression-free survival in men with recurrent prostate cancer, delaying the start of hormone therapy by up to 24 months. The study found minimal side effects and identified biological markers that may predict treatment benefits.
Researchers developed a genomic model to tailor radiation doses to individual patients with HPV-positive throat cancer. The study found that higher scores on the Genomic Adjusted Radiation Dose (GARD) model were associated with improved survival outcomes, even when patients received the same radiation dose.
A new study decodes the mechanism of glioblastoma's resistance to chemotherapy by identifying a HIF-independent circuit built around the epigenetic enzyme PRMT2. Researchers found that combining an existing orphan drug with standard chemotherapy can overcome this resistance, doubling survival without added toxicity.
New research reveals that zebrafish models can help guide clinical decision-making in real-time for challenging pediatric cancer cases. The study shows that pre-clinical zebrafish models accurately predicted responses to 11 of 12 treatment regimens, providing robust and actionable treatment response data.
A study by University of Florida researchers found that 93% of new cancer patients are exposed to at least one type of misinformation about cancer treatments. The most common sources were second-hand information from friends, family, social media, and news outlets. The study suggests that clinicians should assume their patients have be...
Researchers have discovered how Fusobacterium nucleatum binds to human cell receptors CEACAM1 and CEACAM5, which are frequently overexpressed on many types of cancer cells. This binding mechanism is crucial for developing novel antitumor therapies.
Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.
Researchers develop antibody-γδ T cell conjugates to target PD-L1-positive cancers, inducing pyroptosis and remodeling tumor microenvironment. This dual action promotes direct killing of cancer cells and sustained anti-tumor immunity.
A large-scale population study found that oxaliplatin benefits only younger stage III patients, with no added survival benefit for those over 70. The study suggests using an age threshold to make evidence-based choices about chemotherapy.
A new algorithm developed by Núria Malats and her team can accurately predict the presence of metastasis in pancreatic cancer using medical images. The PMPD algorithm has shown promising results, classifying 56% of metastases with high accuracy and potentially avoiding unnecessary surgeries.
Researchers review nuclear receptor role in brain cancer development and explore their potential as therapeutic targets. Modulating these receptors with selective agonists or antagonists may offer new avenues for therapy, such as blocking androgen and estrogen receptors.
A new biotechnical vector, VIBV, combines viral mimicry with synthetic nanotechnology to deliver targeted RNA therapies for cancer treatment. The vector uses a spindle-shaped nanostructure and polyethylene glycolylated liposomal coat to evade immunity and extend circulation.
Researchers found a significant association between financial toxicity and worse emotional and physical well-being among cancer patients. Financial toxicity, which includes stress, expense, and instability caused by healthcare costs, can have far-reaching consequences, including psychological distress and lower quality of life.
A recent study found that RAB26 is mainly expressed in luminal and basal/intermediate prostate cancer cells, correlating with advanced pathological stage and poor patient prognosis. RAB26 promotes proliferation, migration, and invasion of PCa cells while inhibiting apoptosis.
Researchers evaluated a tool based on NCCN Guidelines to identify high-risk medications and their association with frailty and outcomes in over 380,000 older adults diagnosed with cancer. The study found that each additional high-risk medication increased the odds of being mildly or moderately-to-severely frail by 66%.
Researchers create nanoparticles shaped like bottlebrushes with antibodies guiding them to tumor sites, delivering a large range of chemotherapy drugs directly to cancer cells. This approach reduces the need for potent drugs and enhances customizability of treatment options.
Experts weighed in on the current state of artificial intelligence (AI) in cancer care, noting both its potential for improving efficiency and its challenges. Many expressed excitement over AI's possibilities for helping support an overburdened oncology workforce and accelerating the pursuit of new cures.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
A new study published in the American Cancer Society's journal reveals that nearly 1 in 10 patients undergoing surgery for early-stage cancer will initiate opioid prescriptions long-term. The research found that those with a prior history of chronic pain, comorbidities, and lower socioeconomic status were at higher risk.
Research reveals that chemotherapy impairs molecular and behavioral measures of the primary biological clock found in the brain. In a study on female mice, paclitaxel treatment disrupted circadian rhythm-related gene expression and behavioral adaptations to light challenges.
Researchers have identified two molecular targets, HER2 and CD24, as promising candidates for new nuclear diagnostics and therapeutics for endometrial cancer. These targets may help clinicians identify patients likely to respond to targeted therapies, offering new hope for those with disseminated or recurrent disease.
A team of scientists has developed a protein-based therapeutic tool called Crunch to target and remove specific living cells, such as cancer cells or overactive immune cells. The new system uses the body's natural waste removal system to clear out unwanted cells, offering hope for improved treatments.
A study led by Yibin Kang and Yujiao Han reveals that cancer cells hijack a specialized cell to recycle iron, depriving red blood cells of necessary iron and causing anemia. The discovery aims to slow down bone metastasis and alleviate complications.
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
A Mayo Clinic study shows that a shorter, less intense course of radiation and chemotherapy after minimally invasive surgery significantly reduces treatment-related side effects while maintaining high cure rates. The findings apply to intermediate-risk patients, with slightly better disease control in high-risk patients.
Researchers at Northwestern University have developed a new CRISPR delivery system that triples efficiency using DNA-wrapped nanoparticles, improving safety and effectiveness. The new system, called LNP-SNAs, targets specific cells and tissues, reducing toxicity and boosting gene-editing efficiency by threefold.
A study reveals significant global disparities in cancer research funding, with lower-income countries struggling to keep pace. Cancer surgery and radiotherapy research are particularly underfunded, urging a strong case for increased investment.
Human cells use a synchronized traffic control system to monitor nutrient levels and precisely control cellular energy balance, blood sugar levels, and energy management. This finding offers promising new targets for treating diabetes and cancer.
Researchers found that specific nutrient supplements like amino acids, probiotics, and herbs like ginger can effectively reduce nausea, vomiting, and diarrhea. Dietary counseling also showed promise in reducing common GI side effects. Oral nutritional supplements, however, did not demonstrate benefits in easing symptoms.
A new class of targeted therapy showed promise in treating head and neck squamous cell carcinoma (HNSCC) in pet cats, with 35% of patients experiencing controlled disease. The drug, which targets the transcription factor STAT3, also raised levels of PD-1, a protein associated with an immune response to cancer.
Researchers identified a core group of 15 bacterial genera in 6 types of GI tumors that predicts prognosis. Microbiome signals inside tumors carry prognostic and therapeutic information that can be measured on routine tissue. The study suggests a microbiota-based risk score to identify high-risk patients and inform treatment decisions.
A new UCLA-led study finds that government housing assistance reduces the risk of medical bill stress by nearly seven percentage points among US renters with cancer, leading to improved quality of life and reduced poor physical and mental health outcomes.
The EASYGEN consortium will develop a fully automated platform for manufacturing personalized cell therapies within days, accelerating patient access and reducing costs. EBMT is participating in the study examining current CAR-T treatment processes and contributing to patient education and advocacy efforts.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
Researchers evaluated clinical outcomes of endoscopic resection in sellar chondrosarcomas, revealing common symptoms like blurring of vision and headaches. The study also provides recommendations for accurate diagnosis using imaging data and clinical features.
University of Arizona researchers develop a new formulation of paclitaxel, called Paclitaxome, which improves delivery to tumor sites and reduces side effects. The modified drug combination outperforms existing chemotherapy treatments in tests against triple-negative breast cancer and advanced pancreatic cancer in mice.
Researchers at The Mount Sinai Hospital successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma. They identified a combination of compounds approved by the FDA that effectively targeted the lymphoma, with one compound, anti-CCR4, showing particular promise.
A new 'dual-mode' tracer agent shows promise in helping surgeons image and plan prostate cancer procedures while also providing guided surgery with real-time radiation detection. The tracer targets PSMA, a protein highly expressed on prostate cancer cells, offering high-resolution visual guidance and targeted radiation density detection.
Researchers at Mount Sinai Hospital discovered that adding everolimus to standard chemotherapy improves outcomes for patients with advanced triple-negative breast cancer. The combination therapy reduces the risk of disease progression or death by 52%.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
Researchers successfully treat mouse tumor with radioactive carbon ion beam, achieving complete control without major neurological side effects. The BARB project advances image-guided particle therapy using exotic beams, showing feasibility and effectiveness.